Last reviewed · How we verify
Apremilast Oral Product
At a glance
| Generic name | Apremilast Oral Product |
|---|---|
| Sponsor | Tanja Todberg, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients (PHASE2, PHASE3)
- Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (PHASE4)
- A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis (PHASE4)
- Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients (NA)
- Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients (PHASE3)
- Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) (PHASE2)
- A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apremilast Oral Product CI brief — competitive landscape report
- Apremilast Oral Product updates RSS · CI watch RSS
- Tanja Todberg, MD portfolio CI